



GE HealthCare

Invenia™ ABUS Prime


Enterprise breast ultrasound solution for dense breast populations

A scalable, financially efficient ABUS solution built for large enterprises and early cancer detection. It supports efficient multi-site workflows across breast imaging programs and can be paired with ABUS StreamVue™* for centralized, zero-footprint reading — enabling radiologists to read from any anywhere.

Why it matters: Dense breast screening

Dense breast tissue can mask cancers on mammography, potentially delaying diagnosis.^{1,2} Women with dense breasts are also 4–6x more likely to develop breast cancer.³ Invenia ABUS — the first FDA-approved supplemental ultrasound screening technology designed for dense breast tissue — provides a screening solution designed to help reveal cancers earlier and support greater confidence for healthcare providers.

What makes Invenia ABUS a game changer in dense breast screening?



Clinical benefits

- Built for dense breast screening programs
- Supports earlier cancer detection when used alongside mammography⁴
- Standardized 3D ultrasound acquisition ensures consistent image quality⁵
- Unique coronal plane imaging supports precise lesion localization and assessment⁵

Technology highlights

- **Enabled by Verisound™ AI:** Scan Quality Assessment and Auto Nipple Detection for consistent breast volume acquisition
- **cSound™ Imageformer:** Software-based processing for high-resolution, reproducible images across technologists and sites
- **Fast Scan:** Increases scan speed by 40%, improving patient throughput**

Patient experience

- Supports non-invasive, comfortable exams
- **Reverse Curve™ transducer:** Contours to the breast for full contact, comfort, and comprehensive coverage
- Adjustable compression levels to reflect women's individual tolerance level

Economic opportunity

- Implementation may open new economic opportunities and attract additional patient streams⁶
- Reduces operational and IT costs with centralized, zero-footprint viewing
- 2-year warranty for lower lifecycle risk and added program assurance

Invenia ABUS Prime

Offering of 5+ systems

A scalable ABUS solution built for enterprise imaging networks, multi-hospital systems, and high-volume dense-breast programs. Standardized workflows across sites help ensure consistent image quality, reproducible user-independent exams, and reliable performance as your program grows.

Ideal for:



High-volume breast centers



Hospitals with large dense-breast populations



Enterprise imaging networks




Satellite or mobile screening locations***

Read from anywhere with ABUS StreamVue*

ABUS StreamVue delivers centralized, zero-footprint reading designed for flexible, multi-site environments. Server-rendered pixel streaming ensures consistent image presentation while reducing network strain, and the browser-based viewer eliminates local installs or workstation maintenance. Together, these capabilities enable clinicians to read from any location with confidence and allow IT teams to manage systems more simply across the enterprise.

The integration of AI Assistant powered by QVCAD[†] with ABUS StreamVue shows a 33% reduction in reading time⁷ and experiences up to 93% sensitivity for lesion detection.⁸



GE HealthCare supports your dense breast screening program — including implementation guidance, a digital marketing kit, an FDA-approved curriculum, and ABUS Club learning — to speed adoption and elevate care.

References:

*Powered by Candelis.

**Compared to Invenia ABUS 2.0.

***The Invenia ABUS device is not designed for use in a mobile environment unless it is installed using the Mobile ABUS fixation system.

[†]QVCAD is a trademark of QView Medical, Inc.

1. Mandelson et al. *J Natl Cancer Inst* 2000; 92:1081-1087.
2. Tagliafico, Massimo Calabrese et al, *Journal of Clinical Oncology* 2016 34:16, 1882-1888.
3. Boyd NF et al. *NEJM* 2007; 356: 227-36.
4. The Lancet; May 2025; [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(25\)00582-3/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00582-3/fulltext).

5. Grady, et al: Sonographic tomography for the preoperative staging of breast cancer prior to surgery. Elsevier, *Journal of Ultrasound*, 10.1016/j.jus.2010.07.005.
6. GE HealthCare Case Study: Real World Experience and Outcomes with ABUS, Imaging for Women, JB49815XX.
7. Performance and Reading Time of Automated Breast US with or without Computer-Aided Detection. Read more: <https://pubs.rsna.org/doi/10.1148/radiol.2019181816>.
8. Interpretation Time Using a Concurrent-Read Computer-Aided Detection System for Automated Breast Ultrasound in Breast Cancer Screening of Women with Dense Breast Tissue (Yulei Jiang) Read more: <https://www.ajronline.org/doi/10.2214/AJR.18.19516>.

Products mentioned in the material may be subject to government regulations and may not be available in all countries. Shipment and effective sale can only occur after approval from the regulator. Please check with your local GE HealthCare representative for details.

© 2026 GE HealthCare. Invenia, Verisound, cSound, and Reverse Curve are trademarks of GE HealthCare. GE is a trademark of General Electric Company used under trademark license. ABUS StreamVue is a trademark of Candelis.

May 2026
JB13080US



GE HealthCare